Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study

INTRODUCTION: Crohn’s disease (CD) is an inflammatory bowel disease (IBD). Several drugs exist to induce and maintain remission, but a significant part of the patients is refractory to current IBD drugs or experiences side effects. Whether low-dose naltrexone (LDN) is a safe and easily accessible al...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulides, Emma, Lie, Mitchell R K L, van der Woude, Christien Janneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996009/
https://www.ncbi.nlm.nih.gov/pubmed/35396307
http://dx.doi.org/10.1136/bmjopen-2021-058358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996009/
https://www.ncbi.nlm.nih.gov/pubmed/35396307
http://dx.doi.org/10.1136/bmjopen-2021-058358

Ejemplares similares